modernretina

Current and Emerging Treatments for Geographic Atrophy and When to Initiate Therapy

A panelist discusses how interpreting clinical trial data, monitoring disease progression, and maintaining transparent communication help retina specialists make informed decisions about when and how ...
modernretina

AAO 2025: Subretinal drusenoid deposits in Black and Hispanic patients with AMD

The investigators noted that this report is the first about subretinal drusenoid deposits in Black and Hispanic patients with age-related macular degeneration. Researchers from the New York Eye and ...
modernretina

AAO 2025: Ashkan Abbey on the outcomes of EYP-1901 for AMD and DME

Ashkan Abbey, MD, FASRS, FAAO, from Texas Retina Associates discussed EYP-1901, an innovative intravitreal insert that releases vorolanib, a potent tyrosine kinase inhibitor designed to treat retinal ...
modernretina

Leadership in action during the 2025 AAO named lectures

This year, 18 presenters will deliver named lectures during the American Academy of Ophthalmology meeting. Lee M. Jampol, MD, will deliver the lecture “How to Describe New Diseases, the Same Skills ...
modernretina

Kristina Pfau, MD, FEBO

Dr. Kristina Pfau discusses her research on pseudoxanthoma elasticum and the initiatives of EURETINA's Young Ophthalmologist and Retina Specialists Committee.
modernretina

Frank Holz, MD, FEBO, FARVO, highlights new treatment developments at EURETINA

The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life. Frank Holz, MD, FEBO, FARVO, a retina specialist from Bonn, Germany, discusses ...
modernretina

Peter Kaiser, MD, discusses OTX-TKI, a new treatment for wet AMD, introduced by Ocular Therapeutics

Peter Kaiser, MD, from Ocular Therapeutix, introduces OTX-TKI (Axpaxli), a novel tyrosine kinase inhibitor delivered through a proprietary hydrogel platform. This innovative treatment for wet ...
modernretina

Challenges Reported by Young Physicians in Managing Geographic Atrophy and How these Shape Patient Care

A panelist discusses how retina specialists, residents, and fellows manage geographic atrophy by emphasizing early diagnosis, navigating new anticomplement therapies, and improving patient ...
modernretina

The Retina TL;DR: Advancing sustained VEGF suppression with EYP-1901 with Jay S. Duker, MD

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Duker about a sustained-release tyrosine kinase inhibitor that could redefine the durability and ...
modernretina

Charles Miller, MD, PhD, on DME research and the initiation of the phase 2b/3 BRUNELLO trial

Merck and EyeBio launch a pivotal trial for MK-3000, targeting diabetic macular edema with new treatment options to enhance patient outcomes. On September 4, 2025, Merck and EyeBio announced that the ...
modernretina

Fanka Gilevska, MD, PhD

Biomarkers and fine-tuned staging are key to progress in improving retinal care, according to Fanka Gilevska, MD, PhD.
modernretina

Eydenzelt, Celltrion’s biosimilar referencing Eylea, approved by FDA

Eydenzelt is Celltrion's first FDA-approved biologic product in ophthalmology. Eydenzelt is Celltrion's first FDA-approved biologic product in ophthalmology. It was also approved by the European ...